Adapting to Novel Hemophilia A Treatments

EP: 1.Management Insights for Patients With Hemophilia

EP: 2.Coverage Decisions for Expensive Hemophilia Treatments

EP: 3.Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 4.Enhancing Provider Access and Expertise for Rare Disease Care

EP: 5.Factors Impacting Hemophilia A Care Costs

EP: 6.Collaborative Strategies in Hemophilia A Care Cost Management

EP: 7.Strategies to Manage Medication Costs and Waste

Now Viewing

EP: 8.Adapting to Novel Hemophilia A Treatments

EP: 9.Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP: 10.Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP: 11.Hemophilia A Treatment Factors and Outcomes

EP: 12.Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 13.Consequences of Nonadherence in Hemophilia A

EP: 14.Advancements in Hemophilia A Therapies

EP: 15.Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP: 16.Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 17.Emicizumab Dosing: Prophylaxis and Bleeding Management

EP: 18.Optimizing Hemophilia Treatment: Strategies and Adherence

EP: 19.Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 20.Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

Russell P. Gollard, MD, FACP: The new products, particularly those with a novel mechanism of action for treating hemophilia A, are quickly becoming part of our armamentarium for treating the disease. I think that we must change with the times and realize that this is an ever-changing treatment landscape. As newer and better products become available, we must do our best to make these products available to our patients. I have not seen a lot of resistance on the part of health plans to making these important new products available to patients.

Without long-term proven efficacy with a novel agent, how can we change from something that’s proven but imperfect? We need to keep an eagle eye out as clinicians for potential side effects. There have been some drugs that have been pulled off the market, particularly in the case of oncology products, because of really catastrophic toxicities. As astute clinicians, we need to see patients with some frequency and make absolutely certain that adverse effects are reported. In extreme cases, we need to make case reports and send them into journals or send letters out to document them. This is extremely important, and it’s compulsory, and a very important function we fulfill as providers.

Transcript is AI generated and reviewed by an AJMC editor.